Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics

Nov 4, 2022

Announcing a new collaboration with the Frederick National Laboratory for Cancer Research

Dr Bill Eldridge, CEO of Isogenica, and Professor Dong-Hoon Jin, CEO of WMBIO, holding the MoU.


UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA, currently operated by Leidos Biomedical Research, Inc. (FNLCR). The multi-project partnership aims to discover novel molecules that will enable difficult measurements of biomarkers of molecular effectiveness of cancer immuno-oncology agents with clinical laboratory assays.

Isogenica is a biotechnology company specialising in the discovery and optimisation of highly versatile small format antibodies (VHHs), originally derived from camelids, which

are used to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases. VHHs can be readily chained together and assembled to create bi- or multi-specific biotherapeutics, and also used for targeted drug delivery as components of ADCs or in cell and gene therapies including CAR-Ts.

The Isogenica team will be supporting research at the FNLCR with their extensive knowledge and resources in the field of VHH biotherapeutics, contributing to the discovery of clinical solutions to pressing healthcare needs. This partnership will serve as a foundation for cooperation between the two organisations, leveraging each of their strengths and expertise to drive future discoveries.

Director of Business Development at Isogenica, David Mead, says, “We are delighted to enter into a broad partnership with FNLCR, a prestigious institute dedicated in its application of biomedical science to improve human healthcare. The VHH antibodies will provide a unique approach to enhancing the work of FNLCR”.

Further Information

About Isogenica

Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

For further information, visit  

About The Frederick National Laboratory for Cancer Research

The FNLCR works at the forefront of basic, translational, and clinical science with a focus on cancer, AIDS, and infectious disease. The scientists at the FNLCR are conducting a wide array of research; creating new technologies; and collaborating with governmental, industrial, and academic colleagues to efficiently address current public health questions in a novel and unique way. Their work has been instrumental within cancer, AIDS, diagnostics, immunology and many more fields of scientific research. They continue to push to better the lives of people across the world and provide clinical solutions to problems no-one has yet been able to.

Further information, visit: 


Harriet Boyd,
Business Development & Marketing Executive Isogenica

T +44 1799 533 680